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ABSTRACT
N-of-1 trials target actionable mutations, yet such approaches do not test
genomically-informed therapies in patient tumor models prior to patient treatment.
To address this, we developed patient-derived xenograft (PDX) models from fine
needle aspiration (FNA) biopsies (FNA-PDX) obtained from primary pancreatic ductal
adenocarcinoma (PDAC) at the time of diagnosis. Here, we characterize PDX models
established from one primary and two metastatic sites of one patient. We identified
an activating KRAS G12R mutation among other mutations in these models. In explant
cells derived from these PDX tumor models with a KRAS G12R mutation, treatment
with inhibitors of CDKs (including CDK9) reduced phosphorylation of a marker of
CDK9 activity (phospho-RNAPII CTD Ser2/5) and reduced viability/growth of explant
cells derived from PDAC PDX models. Similarly, a CDK inhibitor reduced phosphoRNAPII CTD Ser2/5, increased apoptosis, and inhibited tumor growth in FNA-PDX and
patient-matched metastatic-PDX models. In summary, PDX models can be constructed
from FNA biopsies of PDAC which in turn can enable genomic characterization and
identification of potential therapies.

known as personalized medicine) may present clinicians
with opportunities to improve patient care. Ideally, data
regarding a patient’s tumor could be used in a predictive
manner to inform the clinician of the most appropriate

INTRODUCTION
Precision medicine (using a patient’s unique
genetic and molecular data to inform treatment, also
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therapy. However, there are serious challenges in
translating molecular and genetic data into clinical
practice. Current clinical trials of targeted therapeutics
focus on performance in a patient cohort and cannot
evaluate multiple therapeutic options for individual
patients. To advance precision medicine that benefits
individuals, we must develop robust models to evaluate
the efficacy of potential therapies while the patient is alive.
Patient-derived xenograft (PDX) models address
this unmet need by allowing clinicians to evaluate and
compare multiple therapies. The standard approach to
construct PDX models relies on surgical specimens and
is well characterized in pancreatic ductal adenocarcinoma
(PDAC). [1,2] Such models recapitulate the heterogeneous
tumor morphology, response to chemotherapeutics, and
gene expression patterns observed in patient tumors.
[1,3–9] Engrafting tumors in these models relies upon
factors such as tumor type, cell number, murine host
strain, protocol methodology, and tumor biology. [1,10–
12] In published research, the rates of engraftment and
tumor growth range from 14 to 21 weeks. [1,4,12] In
clinical practice, the short window between diagnosis and
disease progression for aggressive malignancies limits
the application of PDX models from surgical specimens
as a method to evaluate individualized therapies. [13,14]
While technically feasible, construction of PDX models
with surgical specimens from aggressive malignancies
is limited to patients with localized tumors that can be
surgically removed. This is especially true for pancreatic
cancer which is characterized by late presentation and only
a minority (10-15%) of patients present with localized
tumors that are amenable to up-front surgical resection.
One way to address this problem is to establish
PDX models from patients with early-stage disease at the
time of diagnosis. For many cancers, a tissue diagnosis
is established by fine needle aspiration (FNA) biopsy.
This specimen could be used to establish FNA-PDX
models from early-stage disease. At our institution,
patients undergo an endoscopic ultrasound (EUS) with
FNA biopsy to establish a diagnosis of PDAC before
the patient is considered for neoadjuvant therapy and
resection. This biopsy method allows multiple quadrants
within the primary tumor to be targeted for tumor cell
acquisition. The resulting pooled specimen represents
random sampling of tumor cells from the primary tumor
microenvironment. After tissue diagnosis is established,
all patients in our cohort are enrolled onto neoadjuvant
chemoradiation protocols. Therefore, our clinical pathway
does not allow us to obtain treatment naïve tumor tissue
for genomic characterization or PDX engraftment at the
time of surgical resection.
Unfortunately, FNA specimens derived from
primary tumors such as PDAC contain a paucity of tumor
cells mixed with host stromal cells. The FNA specimen
therefore often contains too few tumor cells to perform
genomic profiling. However, PDX tumors derived from
www.impactjournals.com/oncotarget

FNA biopsies provide sufficient material for genomic
characterization. [15] Using targeted sequencing, we
observed that the mutational profile of FNA-PDX tumors
matches that of models derived from patient-matched
peritoneal and liver metastases. Genomic characterization
of these models revealed a KRAS mutation. Increased
RAS pathway signaling by oncogenic KRAS mutations
has been implicated as a driver in PDAC; mutations in
KRAS are found in over 90% of pancreatic tumors. [16,17]
Direct and effective targeting of mutant KRAS in tumors
has thus far not been achieved. [18,19] To circumvent
this challenge, we previously set out to find the Achilles
heel of cells with mutations in the RAS pathway. The
principles of synthetic lethality allow us to treat a tumor
with minimal toxicity to non-cancerous cells by exploiting
vulnerabilities caused by oncogenic alterations. [20–23]
Indeed, this approach has previously been utilized to
discover synthetic lethal interactions in KRAS-mutant
cells. [24] We devised an approach to identify compounds
and experimental drugs that are synthetic lethal with
increased RAS signaling caused by loss of the RASGTPase activating protein (RAS-GAP) NF1. [25] One of
our tool compounds identified in our synthetic lethality
screen shares a target (cyclin dependent kinase 9, CDK9)
with two drugs in clinical trials. [25–27] Here, we show
that FNA-PDX and patient matched metastatic-PDX
models with KRAS mutations are sensitive to inhibitors
of CDK9.
This proof of concept study demonstrates that FNAPDX tumor models can be used to evaluate personalized
therapies such as CDK inhibitors for rapidly progressing
malignancies like pancreatic adenocarcinoma. There are
several challenges for PDX-directed precision medicine.
The models must be established during the clinical
window for aggressive malignancies, they must capture
the clones present within the primary tumor responsible
for recurrence, and they must allow us to compare
therapies before recurrence. Here, we describe an FNAPDX protocol that addresses these challenges.

RESULTS
FNA-PDX models are efficiently engrafted from
FNA specimens at the time of diagnosis prior to
planned neoadjuvant therapy
From December 2011 until May 2014, 34 patients
were consented for FNA-PDX engraftment. 29 patient
FNA specimens were acquired and engrafted into a
subcutaneous flank pocket of a single NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) male mouse. Three patients had nonPDAC histology on final cytopathologic diagnosis and
two patients had metastatic disease diagnosed at the time
of EUS resulting in 24 patient FNA specimens engrafted
from patients with localized biopsy proven PDAC. The
specimen was placed directly into a cryovial on ice. The
17088
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warm ischemia time, defined as the time from FNA biopsy
until placement onto ice, was negligible. The median cold
ischemia time (the time from biopsy until the time of
mouse implantation) was 37 minutes. For patients who
underwent subsequent surgery, tumor tissue was acquired
from either primary tumors or metastatic sites for PDX
engraftment. The clinical protocol and FNA-PDX program
are illustrated in Figure 1.
To date, 9/24 (37.5%) FNA specimens have been
successfully engrafted as PDX tumors. For patients who
were discovered to have metastatic disease upon surgical
exploration, tumor tissue was acquired and 10/10 (100%)
of representative metastatic sites were successfully
engrafted. Once engrafted, all but one FNA-PDX primary
and metastatic-PDX models were successfully passaged
up to the fifth (F5) passage. Once established, frozen PDX
tumors could be thawed and engrafted for in vivo testing
of therapeutic response.

(peritoneal carcinomatosis and liver metastases) were
biopsied and engrafted as metastatic M1 and M2 PDX
models, respectively. This allowed us to characterize FNA
and metastatic-derived PDX models concurrently.
The FNA-PDX tumor resembled the morphology,
glandular formation, differentiation, and the desmoplastic
stroma commonly seen in PDAC. We observed this in
both the F0 (Figure 2A) and F4 (Figure 2B) passages. The
morphologic heterogeneity between the FNA-PDX and
the two metastatic models is depicted by H&E staining.
The tumor contained mouse stromal cells (negative by
human HLA immunohistochemical staining) recruited
by the engrafted tumor cells (positive by human HLA
immunohistochemical staining). The human tumor
cells retained the expression of plectin-1, a putative
PDAC biomarker (Figure 2A,B). [28] The RAS/MAPK
signaling pathway was active, as evidenced by the
immunohistochemical expression of the downstream
effectors phosphorylated MEK and phosphorylated
ERK1/2 (Figure 2A, 2B).
Tumor engraftment and growth characteristics of
the FNA-PDX and patient-matched metastatic M1 and
M2 models are shown in Figure 2C-E. The FNA-PDX F0
tumor took nearly 18 weeks to reach 5 mm in diameter,
while passaged F1-F4 tumors uniformly grew faster
(Figure 2C). Interestingly, the passaged FNA-PDX tumors

FNA-PDX and patient matched metastatic-PDX
tumor morphology and growth rates
We selected patient #008’s FNA-PDX as a proof of
concept for model characterization. This patient is unique
because metastatic disease developed during the time of
FNA-PDX engraftment. Two metastatic sites of disease

Figure 1: Clinical pathway for establishing FNA-PDX models at time of diagnosis of pancreatic ductal adenocarcinoma.

Patients enrolled in this study undergo an EUS-FNA biopsy to establish a diagnosis of PDAC prior to consideration of neoadjuvant
chemotherapy and resection. During this procedure, a pooled FNA specimen is obtained for engraftment into an NSG mouse. This F0
FNA-PDX model is genomically characterized and passaged to further mice to enable evaluation of multiple therapies. Simultaneous to
the development of the FNA-PDX model, patients with a diagnosis of PDAC in our cohort are enrolled onto neoadjuvant therapy protocols
with subsequent resection of the tumor.
www.impactjournals.com/oncotarget
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growth rates were similar to the patient-matched passaged
metastatic M1 (Figure 2D) and M2 (Figure 2E) models.

the F0-F5 passages of the patient #008 FNA-PDX
model (Table 1, Figure 3). Variants detected were then
confirmed by a SNaPshot genotyping assay (Table 1).
Genomic characterization of an FNA biopsy is generally
limited by the paucity of tumor cells. For this patient
there was not enough FNA specimen available after
the clinical diagnostic procedures to perform genomic
characterization. Therefore, we characterized tissue
obtained from the FNA-PDX model as a surrogate of

The FNA-PDX pipeline stably maintains
primary tumor clones that resemble PDX tumors
established from sites of metastases
We used a targeted next-generation sequencing
(NGS) panel that consisted of 48 cancer genes in

Figure 2: FNA-PDX and metastatic-PDX tumor growth and morphology. A-B. Representative images of H&E staining

and immunohistochemical expression of human HLA (a marker specific to cells of human origin), plectin-1 (a marker of PDAC cells),
phosphorylated MEK1/2 and phosphorylated ERK1/2 (markers of RAS pathway activity) in FNA-PDX and metastatic-PDX tumors for
passages F0 (A) and F4 (B). Scale bars: 200 (H&E, p-ERK) μm and 100 μm (HLA plectin-1, p-MEK). C-E. FNA-PDX and patientmatched metastatic-PDX tumor morphology and growth rates of successive passaged tumors.
www.impactjournals.com/oncotarget
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Table 1: Summary of next-generation sequencing of 50 cancer genes from the initial F0 and late F4 passages of FNAPDX #008 (FNA) and patient-matched metastatic-PDX (M1/M2) models. Alleles that were detected but eliminated from
NGS data due to read quality were subsequently validated with a SNaPshot genotyping approach. Italicized variants were
detected at an allelic frequency <10%.
Sample

Gene

Nucleotide Change

AA Change

COSMIC ID

NGS?

SNaPshot?

FNA F0

KRAS

c.34G>C

G12R

COSM518

Yes

Yes

TP53

c.659A>G

Y220C

COSM10758

Yes*

Yes

JAK3

c.2164G>A

V722I

COSM34213

No**

Yes

KRAS

c.34G>C

G12R

COSM518

Yes

Yes

TP53

c.659A>G

Y220C

COSM10758

Yes

Yes

JAK3

c.2164G>A

V722I

COSM34213

Yes*

Yes

KRAS

c.34G>C

G12R

COSM518

Yes

Yes

TP53

c.659A>G

Y220C

COSM10758

Yes

Yes

JAK3

c.2164G>A

V722I

COSM34213

Yes*

Yes

EGFR

c.2219_2220insCATCG

I740_
P741insHR

Yes

No

EGFR

c.2236_2250delGAATTAAGAGAAGCA

E746_
A750delELREA

COSM6225

Yes

No

KRAS

c.34G>C

G12R

COSM518

Yes

Yes

TP53

c.659A>G

Y220C

COSM10758

Yes

Yes

JAK3

c.2164G>A

V722I

COSM34213

Yes

Yes

EGFR

c.2219_2220insCATCG

I740_
P741insHR

Yes

No

EGFR

c.2236_2250delGAATTAAGAGAAGCA

E746_
A750delELREA

COSM6225

Yes

No

KRAS

c.34G>C

G12R

COSM518

Yes

Yes

TP53

c.659A>G

Y220C

COSM10758

Yes

Yes

JAK3

c.2164G>A

V722I

COSM34213

Yes

Yes

KRAS

c.34G>C

G12R

COSM518

Yes

Yes

TP53

c.659A>G

Y220C

COSM10758

Yes

Yes

JAK3

c.2164G>A

V722I

COSM34213

Yes

Yes

EGFR

c.2219_2220insCATCG

I740_
P741insHR

Yes

No

EGFR

c.2236_2250delGAATTAAGAGAAGCA

E746_
A750delELREA

COSM6225

Yes

No

KRAS

c.34G>C

G12R

COSM518

Yes

n/a

TP53

c.659A>G

Y220C

COSM10758

Yes

n/a

JAK3

c.2164G>A

V722I

COSM34213

Yes

n/a

BRAF

c.1405G>C

G469R

COSM455

Yes

n/a

KRAS

c.34G>C

G12R

COSM518

Yes

n/a

TP53

c.659A>G

Y220C

COSM10758

Yes

n/a

JAK3

c.2164G>A

V722I

COSM34213

Yes

n/a

FNA F1

FNA F2

FNA F3

FNA F4

FNA F5

M1 F0

M1 F4

(Continued )
www.impactjournals.com/oncotarget
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Sample

Gene

Nucleotide Change

AA Change

COSMIC ID

NGS?

SNaPshot?

M2 F0

KRAS

c.34G>C

G12R

COSM518

Yes

n/a

TP53

c.659A>G

Y220C

COSM10758

Yes

n/a

JAK3

c.2164G>A

V722I

COSM34213

Yes

n/a

BRAF

c.1405G>C

G469R

COSM455

Yes

n/a

KRAS

c.34G>C

G12R

COSM518

Yes

n/a

TP53

c.659A>G

Y220C

COSM10758

Yes

n/a

JAK3

c.2164G>A

V722I

COSM34213

Yes

n/a

BRAF

c.1405G>C

G469R

COSM455

Yes

n/a

M2 F4

*Variant had coverage below 300x. **Amplicon drop-out.

Figure 3: Next-generation sequencing of passaged FNA-PDX models revealed shared alleles with metastatic sites.

Unobserved tumors (dashed circles) with inferred alleles (grey text) based on sequencing of F0-F5 primary and F0 & F4 metastatic tumors
(black filled circles). Mutations identified as unique to later passage PDX models from the primary tumor are present in early passage PDX
models from metastatic sites. This suggests that passaging of FNA-PDX models selects for tumor cells that match the genetic profile of the
metastatic tumors. *did not meet quality thresholds for NGS and were confirmed by SNaPshot genotyping. **amplicon drop-out by NGS,
confirmed by SNaPshot.
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the primary tumor. In the FNA-PDX F0 and F1 passage,
we identified three variants. One was a TP53 mutation
(Y220C; COSM10758) in which inactivating mutations
have been observed following KRAS activating mutations
in PDACs. [29,30] The TP53 mutation had low coverage,
however it was confirmed with a SNaPshot assay and
Sanger sequencing. The other mutation was a KRAS
mutation (G12R; COSM518) that has been frequently
observed in PDACs. [31] This KRAS allele is an indicator
of poor prognosis in PDACs. [32] A JAK3 mutation
(V722I; COSM34213) was also observed in the F0 FNAPDX model. This mutation in JAK3 has not been reported
in PDAC but has been observed in acute megakaryoblastic
leukemia. [33,34] Due to a limited FNA biopsy sample
size, sequencing of the primary tumor was impossible.
Inferred mutations in the patient tumor in Figure 3 are
labeled in grey text.
Sequencing the FNA-PDX F2-F5 passages indicated
the presence of the same KRAS, TP53 and JAK3 mutations
observed in passages F0 and F1. In passages F2, F3
and F5, we also observed two EGFR mutations (I740_
P741insHR, E746_A750delELREA; COSM6225) that
occurred at an allelic frequency below 10%. The JAK3
mutation was not detected by NGS in the FNA F0 sample
due to amplicon drop-out. EGFR mutations were not
confirmed due to low allelic frequency.
Targeted NGS was also performed on the patientmatched metastatic-PDX models. Sequencing of the
M1 and M2 metastatic-PDX models strongly suggests
that the KRAS, TP53 and JAK3 mutations existed in the
primary pancreatic tumor, as the same KRAS, TP53,
and JAK3 variants were observed in the FNA, M1, and
M2 PDX models (Figure 3). Additionally, sequencing
of the F0 passage of both metastases revealed a BRAF
(G469R; COSM455) mutation. Co-mutation in BRAF
and KRAS in PDAC has been reported by some groups
while others have found that mutations in these two genes
are mutually exclusive. [35–37] The observed BRAF
mutation in the F0 passage of the peritoneal metastasis
(M1) was not detectable in the F4 passage. In contrast,
the BRAF mutation in the F0 from the liver metastasis
(M2) was maintained through the F4 passage. There are
two possibilities consistent with our data; that the variants
present in the F0 FNA-PDX also existed in the primary
tumor, or that they were independently acquired during
engraftment of the F0 FNA-PDX as well as in the process
of engraftment of the F0 M1/M2 metastatic-PDX models.
We consider the former to be more likely, but do not have
the data to distinguish these two possibilities.

tumor (Figure 4A) and from xenograft tumors generated
with cell cultures directly established in vitro from patient
#008’s metastatic pancreatic tumors (M1, Supplementary
Figure S1). We used polymerase chain reaction (PCR)
with human and mouse specific primers to determine
the species composition of the explants (Figure 4A,
Supplementary Figure S1A). We confirmed human content
by immunofluorescence with antibodies against human
leukocyte antigens (HLAs) class I A, B, and C, which
are expressed by most nucleated human cells (Figure 4B,
Supplementary Figures S1B). [38] These methods indicated
that the explants were entirely of human origin and not
mouse stromal origin. Sanger sequencing confirmed that
these cells maintained the KRAS G12R mutation observed
in the M1/M2 tumors (Supplementary Figure S2).

CDK9 inhibition suppresses growth of primary
and metastatic-PDX tumors in vitro and in vivo
We previously used high-throughput screens to
identify drug targets for cancer cells in which increased
RAS signaling due to loss of a RAS-GAP drives tumor
formation. Using this approach we found that cells with
increased RAS signaling are sensitive to inhibition of a
cyclin dependent kinase that phosphorylates RNA Pol
II CTD on Ser2. [25,39] One RNA Pol II CTD Ser2
kinase in humans is CDK9 (the functional subunit of
p-TEFb), for which there are two inhibitors in clinical
trials (dinaciclib and SNS-032). We evaluated the
effect of dinaciclib and SNS-032 on phosphorylation of
RNA Pol II CTD Ser2/5 in explant cells derived from
patient #008’s PDX models. The primary explants
from our M1- and M2-PDX models exhibit RNA
Pol II CTD phosphorylation at Ser2/5 that can be
reduced by treatment with either dinaciclib or SNS032 (Figure 4C, 4D, Supplementary Figure S1C, S1D).
Furthermore, dinaciclib and SNS-032 stopped the in
vitro growth/reduced viability of explants derived from
the PDX models established from metastatic tumors at
concentrations that significantly decreased p-RNAPII
CTD Ser2/5 (Figure 4C–4E, Supplementary Figure S1ES1G).
We then tested whether dinaciclib inhibited
the growth of patient #008’s PDX tumors in vivo by
implanting the FNA-PDX and the metastatic (M1-PDX)
tumors in mice, and treating with dinaciclib or vehicle for
four weeks (Figure 5). Dinaciclib treatment suppressed
the growth of the FNA-PDX and the metastatic M1-PDX
tumors (Figure 5A–5D) decreased phospho-RNAPII
CTD Ser2/5 signal in the tumors, and altered tumor/
stromal morphology (Figure 5E–5H). Dinaciclib treatment
increased apoptosis in FNA-PDX tumors as measured by
caspase-3 cleavage (Figure 5I, 5J). These data suggest
that cells with a KRAS G12R mutation may be vulnerable
to CDK2 and/or 9 inhibition, targets shared by both
dinaciclib and SNS-032.

Low passage explants from PDX models
established in vitro retain the same markers as the
tumor cells in vivo
To rapidly evaluate drug efficacy in tumor cells,
we established explants in vitro from the #008 M2-PDX
www.impactjournals.com/oncotarget
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Figure 4: Explant cells generated from PDX models for rapid testing of targeted therapeutics are sensitive to CDK9
inhibitors. A-B. PCR primers specific to human CHEK1 and mouse Chek1 were used to identify mouse and human content in PDX explant

cells, using U87-MG cells as a human positive control and mouse genomic DNA as a mouse positive control. (A) Cells from a liver metastasis
explant (M2) had human CHEK1 DNA but did not have mouse Chek1 DNA. (B) To validate this, α-Human HLA class 1 A, B, and C expression
(a marker of cells of human and not mouse origin) were examined by immunofluorescence. All M2 explant cells evaluated were found to be
α-Human HLA A, B and/or C positive. Human (H522) and mouse (ED1L) cell lines were used as controls. Scale bar: 20 μm. C. A KRAS
mutant PDX explant treated for 24 h with the CDK9 inhibitors dinaciclib (10 nM and 200 nM) and SNS-032 (50 nM and 200 nM) has reduced
Ser2/5 phosphorylation of the CTD of the large subunit of RNAPII. Scale bar: 20 μm. D. Box plots of the quantification of total fluorescent
intensity per unit area of cells treated with dinaciclib and SNS-032 and stained for p-Ser2/5 RNAPII CTD. Data presented was collected in
three independent experiments. E. Dinaciclib (IC50: 13 nM) and SNS-032 (IC50: 165 nM) inhibit the growth of explant cells during a 3 day
treatment. Data presented is the average fluorescence and corresponding standard error of the mean for three independent experiments.
www.impactjournals.com/oncotarget
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Figure 5: Dinaciclib inhibits tumor growth in KRAS mutant FNA-PDX and metastatic-PDX models. A-D. Dinaciclib

inhibits the growth of FNA-primary and patient-matched metastatic-PDX tumors in vivo. (A) FNA-PDX models established from the patient’s
primary tumor were treated with 40 mg/kg dinaciclib (top) or vehicle (bottom) 3 times per week for 4 weeks when the tumor reached 62.5
mm3. Tumors were excised. (B) Loess regression curve of the tumor growth of FNA-PDX models from (A) during treatment with vehicle
(red) or dinaciclib (blue). 95% confidence intervals are indicated by the grey region. (C) PDX models established from a peritoneal metastasis
(M1 from Figure 3) were treated with 40 mg/kg dinaciclib (top) or vehicle (bottom) and tumors excised after 4 weeks of treatment. (D) Loess
regression curve from (C) during treatment with vehicle (circles) or dinaciclib (squares). 95% confidence intervals are indicated by the grey
region. E-F. Representative H&E and p-RNAPII CTD Ser2/5 immunohistochemical staining of FNA-PDX tumor sections from vehicle treated
mice. Tumors treated with dinaciclib exhibit reduced p-RNAPII CTD Ser2/5 as compared to the vehicle control. (G-H) Representative H&E
and p-Ser2/5 RNAPII CTD immunohistochemical staining of metastatic-PDX tumor sections from dinaciclib treated mice. I-J. Representative
cleaved caspase-3 immunohistochemical staining in FNA-PDX tumors from vehicle (I) and dinaciclib treated mice (J).
www.impactjournals.com/oncotarget
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DISCUSSION

undergo neoadjuvant therapy or surgery, the median
time to recurrence is 1 year and 80% recur in 2 years.
[43,44] We demonstrate the establishment of FNA-PDX
models within this window. While the patient is receiving
standard therapies, FNA-PDX models allow molecular
characterization and testing of therapeutics to inform
treatment options at the time of disease recurrence.
Tumor heterogeneity complicates the use of
genomic assays for personalized medicine. [45–47]
To establish FNA-PDX models, we targeted multiple
quadrants of the tumor during the FNA biopsy for spatially
diverse sampling of tumor cells within the primary
tumor. [48–50] We hypothesized that engraftment of this
sample would select for the clinically relevant clone in
the FNA-PDX model. Other groups have demonstrated
genomic stability in PDX models. [51] The stability of the
model is critical if a patient’s PDX model will be used to
inform therapy or for drug stability. To address this issue,
Tignanelli and Yeh and colleagues showed stability of
mutational frequencies in late passaged colorectal cancer
and pancreatic cancer PDX models. [51] We also observed
that a PDX model established from an FNA biopsy was
genetically stable between the F0 and F5 passages.
The FNA-PDX model had genetic features that were
observed in the metastatic-PDX models. This suggests
that xenotransplantation of FNA-PDX tumors permits the
growth of clones represented in the patient’s metastatic
sites. It also suggests that PDX models generated from
the FNA biopsy of the primary tumor closely represents
the clones with metastatic and invasive potential. Our
data show that the response of the FNA-PDX to targeted
therapies is recapitulated in patient-matched PDX models
established from a metastatic site. These results in the
FNA-PDX model may also show activity at the time of
recurrence in a metastatic setting.
In conclusion, we show that FNA-PDX and patientmatched metastatic-PDX models with KRAS mutations
are sensitive to CDK9 inhibitors. This work illustrates
that FNA-PDX models present significant opportunities to
evaluate personalized treatments before disease recurrence
for aggressive and difficult-to-treat malignancies. We
show that FNA-PDX models can first, be efficiently
established during the clinical window for aggressive
malignancies, second, capture the clones present within
the primary tumor with metastatic potential, and third,
provide a platform for comparing genome-driven therapies
before recurrence.

We constructed PDAC PDX models from FNA
biopsies. In the FNA-PDX tumor, we identified molecular
lesions that predicted response to targeted therapies (CDK9
inhibition) identified through high-throughput screens.
CDK9 loss in yeast was previously found to be synthetic
lethal with increased Ras pathway signaling resulting
from loss of the RAS-GAP NF1. [25] We observed that
KRAS mutant FNA-PDX and metastatic-PDX explant
cells had phosphorylation of Ser2/5 of the large subunit of
RNAPII, and phosphorylation was reduced with two CDK9
inhibitors, dinaciclib and SNS-032. Dinaciclib, an inhibitor
of CDKs 1/2/5/9, was previously evaluated as a CDK5
inhibitor in PDAC PDX models from surgical specimens.
[2] SNS-032 has been shown to be selective for CDKs 2/7/9
at the effective concentration used in our study. [40] These
inhibitors reduced the growth of PDX explant cells in vitro.
We observed that dinaciclib inhibited tumor growth and
induced cell death in both FNA-PDX and metastatic-PDX
models. Furthermore, dinaciclib inhibited CDK9 in these
PDX tumors as indicated by a reduction in phosphorylation
of Ser2/5 of the large subunit of RNAPII. Taken together,
these results suggest that dinaciclib’s effect on growth of the
KRAS-mutant FNA and metastatic pancreatic PDX models
is due to inhibition of CDK2 and/or CDK9.
One major challenge that limits PDX application to
individualized treatments in PDAC is tissue acquisition.
To date, most PDX protocols require surgery, even for
localized tumors, to obtain enough tissue for engraftment.
[41] However, only a minority of patients presenting
with biopsy proven PDAC can be considered for up-front
surgical resection. Many patients with localized tumors
cannot be considered for surgical resection due to age,
comorbidities and declining performance status. For
aggressive cancers, such as pancreatic and lung cancer,
patients often never undergo surgery before starting
systemic treatment. Kim et al. established PDX models
from surgically resected tumors in patients treated with
neoadjuvant therapy. [9,42] However, in order for PDX
models to be used to inform patient therapy, these models
need to be established from primary tumor tissue before
the patient’s tumor is subjected to either chemotherapy or
chemoradiation therapy. One source of treatment-naïve
tumor tissue is the FNA biopsy performed at diagnosis
of PDAC. While FNA biopsies can establish a tissue
diagnosis with excellent sensitivity and specificity there
is often limited cellular material available for molecular
diagnostic or research studies. In the present study, we
demonstrated engraftment of EUS-FNA biopsies from
treatment-naïve primary pancreatic tumors into FNA-PDX
models, enabling characterization and testing of therapies.
A second major challenge to using PDX models
to inform therapy in aggressive malignancies is the
narrow window from the time of diagnosis to disease
progression. For patients with localized PDAC who
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Establishing PDX models
Beginning in December of 2011, Velos protocol
number D11129 (CPHS 23034/IACUC 11-01-05) protocol
began accrual. At our institution, patients presenting with
a pancreatic mass and without metastatic disease on cross
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sectional imaging were considered for EUS/FNA biopsy to
establish a tissue diagnosis prior to multidisciplinary review
and consideration for Dartmouth-Hitchcock/Norris Cotton
Cancer Center neoadjuvant therapy protocols. FNA-PDX
protocol consent was obtained before the procedure. Once
cytopathologic diagnosis was confirmed by on-site review
a 2nd or 3rd pass/repeat EUS/FNA biopsy was obtained
for tumor cell acquisition. Patient demographics, EUS
findings, cytopathology acquisition numbers, procedure,
and specimen acquisition times were recorded. The FNA
specimen was placed immediately on ice.
FNA specimen was washed with ice-cold DMEM
(Hyclone, South Logan, UT, USA) containing 1%
penicillin/streptomycin (Hyclone), centrifuged at 2000rpm
x 2 minutes and resuspended in 50 μL DMEM. We placed
an 8-12 week old male NSG mouse under isoflurane
anesthesia and opened a small pocket on its right flank.
The entire pooled FNA specimen was transplanted to a
single NSG mouse flank as a heterotopic implantation.
Briefly, through a small flank incision we created a
subcutaneous pocket wherein the FNA specimen was
implanted surgically. Tumor progress was measured three
times weekly until the tumor reached 10 mm2. This initial
PDX tumor was designated F0 as described by Monsma
et al, Malaney et al and others. [10,52,53] The tumor was
then passaged to bilateral flanks of two subsequent mice.
Passaged tumors and mice were designated F1-F7, and
portions of tumor tissue were banked in 10% phosphatebuffered formalin (Polysciences, Warrington, PA, USA)
for paraffin embedding, liquid nitrogen, and RNAlater
(Qiagen, Valencia, CA, USA). Tissue was also banked at
-140°C in FBS with 10% DMSO for later use in in-vivo
experiments. All mouse procedures followed Institutional
Animal Care and Use Committee protocols. Mice were
raised in the Transgenics and Genetic Constructs Resource
at Dartmouth College.

1:50), phospho-p44/42 MAPK (ERK1/2) Thr202/
Tyr204 (Cell Signaling, 1:300) p-RPB1 CTD Ser 2/5
(Cell Signaling; 1:25-1:200). Appropriate controls were
performed on tumor sections without primary antibody
(data not shown).
Phospho-MAPK p44/42 antibody incubation was
performed overnight. Plectin-1 and p-MEK primary
antibody incubation was followed by a 30-minute
incubation with the secondary antibody (RT, 1:200).
The HLA secondary antibody incubation was preceded
by a 10-minute peroxide block. Secondary staining for
p-MAPK p44/42 and p-Rpb1 CTD Ser 2/5 was performed
with SignalStain Boost Reagent, Rabbit (Cell Signaling).
After a 30-minute incubation with the ABC reagent
(Bethyl Lab Inc, all antibodies except p-MAPK p44/42
and p-RPB CTD S2/5), slides were developed with DAB
(BD Pharmingen, San Jose, CA, USA) and counterstained
with hematoxylin/Scott’s bluing reagent. H&E, cleaved
caspase-3, and p-RPB CTD S2/5 slides were evaluated by
a GI pathologist.

DNA extraction, next generation sequencing, and
SNaPshot assay
Genomic DNA was extracted using the Gentra
PureGene Kit (Qiagen, Valencia, CA, USA). Samples
were quantified by Quant-iTTM PicoGreen® dsDNA Assay
Kit (Life Technologies, Grand Island, NY, USA) before
next generation sequencing. Sample preparation and
sequencing was performed by a CLIA-approved molecular
pathology core facility. Libraries were generated using
the llumina TruSeq Amplicon Cancer Panel that consists
of 212 amplicons mapped in 48 genes. At least 250 ng
of DNA was used for the hybridization of oligo probes
through the targeted region of genomic DNA, followed
by extension and ligation, resulting in the formation of
products containing the targeted regions of interest flanked
by sequences required for amplification. Indices and
sequence adapters were added by PCR. Finally, libraries
were purified, normalized (to ensure equal representation
of each sample), pooled, and sequenced on the Illumina
MiSeq system. The average cluster density was 1074.9 K/
mm2, with 91.92% of the clusters passing quality control
filters. Approximately 97.7% of the clusters were ≥Q30
(Phred quality score).
Base-calling and sequence alignment to hg19
were performed using the MiSeq reporter software. VCF
files were generated using the Somatic Variant Caller
for the TruSeq Amplicon Cancer Panel. VCF files were
then uploaded to VariantStudio v2.1.36, where variants
were annotated, classified, and filtered for quality and
significance. The initial step of the filtering process was to
remove non-coding or low-quality variants (quality score
<100). An additional filter was then applied to remove
those that were present at less than 7.5% allelic frequency
or were covered at less than 300x. Remaining variants were

Immunohistochemistry
Immunohistochemistry was performed on paraffinembedded tissue (5 μm sections). After deparaffinization
in xylene and rehydration in decreasing concentrations
of EtOH, slides were boiled in Epitope Retrieval Buffer
(Bethyl Lab Inc., Montgomery, TX, USA) for either 20
minutes (HLA) or 30 minutes (plectin-1, p-MEK, p-RPB1
CTD S2/5). Tissue permeabilization in 0.5% Triton-X
100/1% TBS was followed by either a 0.3% peroxide
block in methanol (plectin-1, p-MEK, p-RPB1 CTD
S2/5) or a normal serum block (HLA). After avidin/biotin
blocking (Vector Labs, Burlingame, CA, USA), slides
were incubated with the primary antibody overnight at 4°C
or 1 hour at RT (p-RPB1 CTD Ser 2/5). Primary antibody
dilutions were: HLA Class 1 ABC (Acris Antibodies Inc,
San Diego, CA; 5 μg/mL), plectin-1 [E398P] (Abcam,
San Francisco, CA, USA; 1:1000) and phospho-MEK1/2
Ser221(166F8) (Cell Signaling, Danvers, MA, USA;
www.impactjournals.com/oncotarget
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individually interrogated using the UCSC Genome Browser
GRCh37/hg19 assembly (http://genome.ucsc.edu).
In order to confirm the variants detected by NGS,
we designed a genotyping panel using the SNaPshot
technology. SNaPshot is a multiplex genotyping assay that
consists of multiple steps, which includes a multiplexed
exon specific PCR using unlabeled oligonucleotide primer
sets and a multiplexed single-base primer extension using
fluorescently labeled dideoxynucleotide triphosphate. For the
PCR, we designed primers for the following genes: EGFR,
KRAS,JAK3, and TP53. For the extension PCR, we designed
a total of three primers for the point mutations and two for the
INDEL. Samples were normalized to approximately 10 ng/μl
and approximately 20 ng of gDNA was used for the reaction.
All samples, and a positive control for each mutation were
amplified with unlabeled primers for genes and subjected to
a multiplexed extension primer reaction using the SNaPshot
Ready Reaction Mix (Life Technologies). Capillary
electrophoresis of PCR products was performed using the
ABI 3500 Genetic Analyzer with POP-7TM polymer and
50 cm capillary. The genotyping results were analyzed using
Applied Biosystems GeneMapper® 4.1 software.
PCR primers:
KRAS (exon 2):
Forward: TCATTATTTTTATTATAAGGCCTGCTG
Reverse: AGAATGGTCCTGCACCAGTAA
EGFR (exon 19):
Forward: GCACCATCTCACAATTGCCAGTTA
Reverse: AAAAGGTGGGCCTGAGGTTCA
TP53 (exon 6):
Forward: AGGTCAAATAAGCAGCAGGAG
Reverse: CACTGATTGCTCTTAGGTCTGG
JAK3 (exon 16):
Forward: CTCAGTGCTCACCGACAGGA
Reverse: AAAGTGGGGGTTCGGAGAC

Tewksbury, MA, USA) and cultured at 37°C in humidified
5% CO2. Media was changed every three to four days.
Once cells reached 60-70% confluence, cells were
trypsinized with a 0.05% trypsin (Cellgro) solution. In an
attempt to isolate tumor cells from contaminating mouse
stromal cells in early passage cell cultures, we monitored
the trypsin incubation step under the microscope for
differential adherence of cell populations. Less adherent
mouse stromal cells were washed with cold PBS, aspirated
and discarded to enrich the remaining adherent tumor cell
population which was subsequently replated in DMEM
with 10% FBS at 1-1.56 cells per 175cm2 flask. Early
passage cell cultures were tested for mycoplasma, HIV
and hepatitis B and C tested prior to in vitro studies.

Cell lines
Cell lines used as controls were obtained from the
American Type Culture Collection (H522, U87-MG) or
were a kind gift from Dr. Ethan Dmitrovsky (ED1L). Cells
were cultured in RPMI 1640 (Corning, H522/ED1L) or
DMEM (Corning, U87-MG) with 10% fetal bovine serum
(Atlanta Biologicals, Flowery Branch, GA, USA). Cell
lines were maintained at 37°C in humidified 5% CO2.

Immunofluorescence
Tumor explants were cultured on poly-D-lysine
coated coverslips (Neuvitro Corporation, El Monte,
CA, USA) and treated with dinaciclib (Izen Biosciences
Pvt Ltd, Hyderabad, India) or SNS-032 (Selleckchem,
Houston, TX, USA) for 24 hours. Cells were fixed in 3.7%
formaldehyde (Fisher Scientific, Pittsburgh, PA, USA) in
PBS (Corning) and blocked with IF buffer (2%[v/v] goat
serum, 0.2%[v/v] Triton X-100 and 0.05%[w/v] sodium
azide in PBS) at RT. Ser2/5 phosphorylation of the CTD
of the large subunit of RNAPII was labeled using 1:400
rabbit anti-phospho-Rpb1 CTD Ser 2/5 #4735 at room
temperature for one hour (Cell Signaling) and 1:800 goat
anti-rabbit F(ab’)2 DyLight 594 at room temperature for
1 hour (Thermo Scientific, Waltham, MA, USA) diluted
in IF buffer. Images were acquired with a Zeiss Imager
Z1 wide-field microscope equipped with a 40x 1.3 NA
EC Plan-NEOFLUAR objective and Zeiss Axiovision
software.
Immunofluorescence images were composited/
measured using Fiji. [54] We used previously described
methods to quantify fluorescent intensity. [55,56] Each
measured region was defined with DAPI channel. The
same size region was measured next to the cell for the
background reading. Fluorescence intensity measurements
were performed on cells stained for p-RPB CTD Ser2/5.
For comparisons between cells, we calculated corrected
total fluorescence (CTCF) for each cell, which is the
integrated density of cell minus area of selected cell times
mean fluorescence of background readings for that cell.

SNaPshot primers:
KRAS (p.G12R): GACTGACTGCTCTTGCCTACGCCAC
EGFR (c.2236_2250del15, forward): CTGACTGACTG
ACTGACTGTCCCGTCGCTAT-CAAG
EGFR (c.2236_2250del15, reverse): GACTGACTGACTG
ACTGACTGACTGACTGAC-TGACTGACTGATTGGC
TTTCGGAGATGT
TP53 (p.Y220C): GACTGACTGACTGACTGACTGACT
GACTGACTAGTGTGGTGGT-GCCCT
JAK3 (p.V722I): GACTGACTGACTGACTGACTGACT
GACTGACTGACTGACTGACTG-ACTGACTGACTGA
CTGACTGACTGAGAAGTGTTTAGTGGC

Establishing low passage in vitro cell cultures
from PDX models
When tumors were passaged, a separate aliquot of
tumor tissue was minced in DMEM (Hyclone) containing
10% FBS (Hyclone) and 1% penicillin/streptomycin
(Hyclone) and placed into a 6-well plate (Corning,
www.impactjournals.com/oncotarget
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Response to drugs in vitro

We divided the value by the area of each cell to correct
for cell size. This value was averaged over 100 cells for
each of 3 replicates. All data are accessible via a publically
available repository (doi: 10.5281/zenodo.34430). [57]

To perform drug sensitivity assays, cells were
plated to 96-well plates at a concentration of 5000 cells/
well. After overnight incubation, medium was removed
and replaced with 100 μL of medium containing 0-2000
nM CDK9 inhibitor and DMSO (to normalize DMSO
concentrations) was added. Cells were incubated for 3 days
with a final 3-hour incubation in 5% AlamarBlue (Thermo
Scientific). The plate was scanned at an Ex/Em of 544/590
nm, and fluorescence was normalized to vehicle control
wells. Dose-response curves and IC50s were calculated
with the Prism 6 software package (GraphPad, San Diego,
CA, USA) by performing a 4-parameter logistic regression
with outlier exclusion analysis.

Characterization of explant cell lines
Tumor explants were cultured on poly-D-lysine
coated coverslips (Neuvitro Corporation) and allowed to
adhere overnight. Cells were fixed in 3.7% formaldehyde
and blocked with IF buffer at RT. Cells of human origin
were labeled using 1:200 rat anti-human HLA Class I ABC
#SM2012P for one hour at RT (Acris Antibodies) and 1:100
goat anti-rat FITC for one hour at RT (Sigma-Aldrich, St.
Louis, MO, USA) diluted in IF buffer. Images were acquired
with a Zeiss Imager Z1 wide-field microscope equipped
with a 40x 1.3 NA EC Plan-NEOFLUAR objective. Images
were processed and composited with Fiji. [54]
PCR was performed using primers directed towards
mouse Chek1, human CHK1 (introns 3 and 6) and human
KRAS. Species specific Chek1/CHK1 primers were used
to confirm that the PDX-derived explant cells were of
human origin. DNA extraction was performed in lysis
buffer (0.45% Nonidet P40 [Roche, Nutley, NJ, USA],
1X ThermoPol Taq buffer (New England Biolabs, Ipwich,
MA, USA), and 100 μg/mL proteinase K [Roche]) at
55°C. Amplification was performed in a 20 μL reaction
volume including 1 μL DNA extract, 0.5 μM forward
and reverse primer mixture, 200 μM dNTPs, 0.1 unit
Taq DNA Polymerase (New England Biolabs), 2 μL 10X
Standard Taq Buffer (New England Biolabs), and 15 μL
nuclease-free water. The thermocycler protocol was as
follows: 1. (94°C, 2 minutes), 2. (94°C, 15 seconds), 3.
(58°C (CHEK1) or 52°C (KRAS), 30 seconds), 4. (72°C,
1 minute, 5. (72°C, 10 minutes), with steps 2-4 repeated
for 30-40 cycles. Amplified DNA and a 100 kb ladder was
run on a 1.5% TBE-agar gel with ethidium bromide for
40 minutes at 100 V and visualized with UV light. Sanger
sequencing of KRAS was performed by the Dartmouth
College Molecular Biology core facility using 5 pmol
KRAS reverse primer and 20ng KRAS PCR product.
Sequence chromatographs were visualized using 4Peaks.
Primers:
Mouse Chek1:
Forward: 5’-ccacagtctcagtgaagggc-3’
Reverse: 5’-gaagaaaaagtaaaaggcatcg-3’
Human CHEK1, intron 3:
Forward: 5’-atgacgccttttgccaccta-3’,
Reverse: 5’-cacccctgccatgagttgat-3’
Human CHEK1, intron 6:
Forward: 5’-cttactgcaatgctcgctgg-3’,
Reverse: 5’-gggtaccatggctcatgtct-3’
Human KRAS [58]:
Forward: 5’-aaggtactggtggagtatttg-3’
Reverse: 5’-gtactcatgaaaatggtcagag-3’
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Response to drugs in vivo
FNA-PDX and metastatic-PDX models were
established as described above. Mice were assigned
to vehicle (20% hydroxpropyl-β-cyclodextrin, SigmaAldrich) or dinaciclib treatment arms ensuring that both
groups had an equal distribution of tumor sizes. Treatment
was initiated when tumors reached approximately 62.5
mm3. Mice were weighed prior to treatment and treated
3 times weekly i.p. with 40 mg/kg dinaciclib in 20%
hydroxypropyl-β-cyclodextrin or an equivalent amount of
vehicle for 4 weeks. Mouse weight and tumor dimensions
were measured prior to every treatment and volumes were
calculated using the following formula:
Volume = ½ (L x W2)

Statistical methods for data analyses
Box plots were constructed using ggplot2 and the
R programming language. [59,60] Tumor volumes over
time were modeled using LOESS regression in R. [59]
This technique models tumor volume over time using local
measurements. 95% confidence intervals (grey regions)
were calculated using the T approximation. All data are
accessible via publically available repository (http://
dx.doi.org/10.5281/zenodo.34430). [57]
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